Are sleepless nights ahead for US FDA in wake of off-label narcolepsy drug verdict?
This article was originally published in SRA
US drug and device regulators kept quiet the day after a federal appeals court ruled that the "truthful" off-label promotion of US approved prescription drugs is not criminal activity and is protected speech under the First Amendment of the US Constitution, but Washington lawyer John R Fleder suspects there likely were quite a few nervous discussions and emails being circulated among officials at the Food and Drug Administration and the Department of Justice1-3.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.